NEPHROS INC

Company Overview

Nephros Inc. (NEPH) designs and sells high-performance water purification products—primarily polysulfone hollow-fiber ultrafilters and carbon/ancillary filters—for medical (hospitals, dialysis clinics) and commercial customers. The company is small and concentrated (31 employees) with recurring replacement demand (typical in‑use lives of 3–12 months), meaningful customer concentration (top two customers ~33% of 2024 revenue), and reliance on a single major medical manufacturing partner (Medica) under a supply/license agreement extended through 2028. Recent filings show modest revenue stability transitioning into stronger programmatic reorders in 2025, expanding gross margins (~62–64%) and a tightening of SG&A that moved the company to small net income in 2024 and better profitability in early 2025.

Executive Compensation Practices

Given Nephros’s size, cash constraints and stage, executive pay appears to be a mix of cash salary plus variable components (bonuses, commissions) and meaningful equity-based compensation; management disclosed that lower stock compensation and bonus accruals materially reduced SG&A in 2024. Compensation is likely tied to near-term commercial metrics that management emphasizes: programmatic reorder growth, gross margin improvement (supplier pricing/mix), and cash preservation/runway (management repeatedly cites 12‑month cash adequacy). As the company scales commercial distribution after ending an exclusive distributor and grows recurring sales, expect higher commission and bonus accruals tied to sales KPIs and potentially a gradual re‑introduction or repricing of long‑term equity incentives to retain sales/R&D talent while balancing dilution and liquidity concerns.

Insider Trading Considerations

Nephros’s small size, concentrated customer/supplier relationships and periodic “lumpy” emergency orders make material information events (large remediation contracts, supplier pricing changes, 510(k) or CMS/regulatory developments) especially likely to move the stock; insiders trading around such events warrant extra scrutiny. Because management has used equity compensation and the company’s cash runway is a recurring disclosure, insiders may sell for personal liquidity when cash balances are tight or buy to signal confidence after improving cash/margin disclosures; look for pre‑arranged (10b5‑1) plan filings which are common in thinly traded small caps. Regulatory windows and FDA/CMS disclosures are critical — device‑industry rules (QSR/GMP, 510(k) clearances) create natural blackout periods and materiality triggers that should precede public disclosure before insiders trade.